Immedica Pharma US Inc.
Immedica Pharma US Inc., formerly Marinus Pharmaceuticals, is the US pharmaceutical subsidiary of Immedica Pharma AB, focused on medicines for rare neurological and metabolic diseases. Its products include ZTALMY (ganaxolone), an oral treatment for seizures associated with CDKL5 deficiency disorder, and Loargys (pegzilarginase-nbln). Immedica acquired Marinus in February 2025, and the business now operates from Chicago.
Key facts
๐AngelListโBlogcbCrunchbasefFacebookinLinkedInpbPitchBook๐Seedtable๐X๐WebsiteโถYouTube
| Also Known As | Marinus Pharmaceuticals, Inc. |
|---|---|
| CAGE Code | 4BX80 |
| Legal Name | Marinus Pharmaceuticals, Inc. |
| Company Operating Status | Acquired |
| Full Address | 5 Radnor Corporate Center, 100 Matsonford Rd, Suite 500, Radnor, PA 19087, US |
| Stock Symbol | MRNS |
| Ticker Symbol | MRNS |
| Wellfound ID | marinus-pharmaceuticals |
Contact details
Email and phone for Immedica Pharma US Inc. are available to signed-in members of CliffBio.
Sign in to view